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ABSTRACT
Hematopoietic stem cell transplantation (HCT) in patients with prior or active invasive aspergillosis (IA) is a
frequent consideration. We reviewed outcomes of 2319 patients who underwent transplantation between 1992
and 2001 in our institution, among whom 45 patients (1.9%) had a known history of IA before HCT.
Posttransplantation IA occurred in 13 of these 45 patients with a pretransplantation history (29%). Nine
infections were considered recurrent by anatomic site and timing. Compared with all other patients who
received allogeneic HCT during the same period, patients with histories of IA had lower overall survival (56%
versus 77%; P  .0001) and higher transplant-related mortality (TRM; 38% versus 21%; P  .0001) 100 days
after HCT, associated mainly with IA and other pulmonary complications. Among patients with prior IA,
posttransplantation IA occurred more frequently in patients who received <1 month of antifungal therapy
before HCT (4/6 versus 6/39; P  .001). The probability of posttransplantation IA and overall survival among
patients who received >1 month of antifungal therapy and had resolution of radiographic abnormalities were
not different from those of patients without prior IA. Patients with prior IA who received conditioning with
total body irradiation (TBI) had higher TRM compared with those who received nonmyeloablative and
non–total body irradiation–based regimens (16/31 versus 2/14; P  .024). Thus, the duration of antifungal
therapy before transplantation, the resolution of radiographic abnormalities, and conditioning regimens are
important variables to consider for minimizing the risk for IA recurrence and TRM after allogeneic HCT.
© 2004 American Society for Blood and Marrow Transplantation
KEY WORDS
Invasive aspergillosis ● History ● Allogeneic ● Hematopoietic cell transplantationb
f
p
t
p
o
t
o
s
pNTRODUCTION
With the use of increasingly intensive chemother-
py regimens for the induction and consolidation of
ematologic malignancies, more patients referred for
ematopoietic stem cell transplantation (HCT) have a
istory of infections, including invasive aspergillosis
IA) [1]. Because of the perceived high risk of recur-
ent IA and transplant-related mortality (TRM), con-
entional allogeneic HCT can be considered contra-
ndicated in such patients [2]. Factors predicting
utcomes in patients with prior infection have not [
94een fully elucidated, but more knowledge may allow
or development of better transplantation and sup-
ortive care strategies. The only study published for
his purpose to date is a retrospective survey of 48
atients with histories of IA before allogeneic (n 36)
r autologous (n  11) HCT [3]. In this study, inves-
igators reported an IA recurrence rate of 33%, with
utcomes dependent on conditioning regimens;
peciﬁcally, conditioning with busulfan and cyclo-
hosphamide was associated with beneﬁcial outcomes
3]. We and others have previously reported successful
t
u
t
a
p
b
t
a
[
t
c
a
t
t
a
m
c
P
S
H
t
t
D
H
t
p
t
s
s
R
t
e
b
v
m
w
p
i
p
r
f
l
t
a
t
w
s
b
p
w
s
n
h
a
(
m
c
l
f
p
i
t
P
t
i
t
a
s
p
4
t
i
g
a
p
n
m
w
D
p
g
M
d
d
i
i
s
p
w
w
t
t
o
a
w
S
T
d
r
t
c
t
Invasive Aspergillosis before Allogeneic HSCT
Bransplantation in patients with prior pulmonary IA by
sing nonmyeloablative or reduced-intensity condi-
ioning regimens [4-6]. Supportive care practices may
lso alter risks for recurrent infection; review of re-
orted cases suggests that risks of recurrent IA might
e reduced by the use of prophylactic granulocyte
ransfusions, surgical resection of lung lesions, and
ggressive antifungal prophylaxis after transplantation
5,7-16].
In this retrospective study, we sought to determine
he outcomes of ﬁrst allogeneic HCT among a large
ohort of patients (n  2319) in our institution with
nd without a known history of IA before transplan-
ation. With the goal of ultimately developing better
herapeutic strategies, we evaluated pretransplantation
nd posttransplantation therapeutic variables that
ight be associated with posttransplantation out-
omes in patients with pretransplantation IA.
ATIENTS AND METHODS
tudy Patients
To identify patients with histories of IA before
CT, we reviewed the infectious diseases consulta-
ion records and computerized databases of all pa-
ients who received ﬁrst allogeneic HCT between
ecember 1, 1992, and May 15, 2001, at the Fred
utchinson Cancer Research Center. During this
ime, consultation with Infectious Diseases was usually
erformed to evaluate all patients with severe oppor-
unistic infections before HCT. Patients who received
yngeneic or autologous grafts were not included. The
tudy was approved by the Fred Hutchinson Cancer
esearch Center Institutional Review Board.
Transplantation was performed according to ac-
ive institutional protocols. Patients were conditioned
ither with high-dose total body irradiation (TBI)–
ased (n  1474) or non–TBI-based (n  745) con-
entional regimens or with nonmyeloablative regi-
ens (n  100) consisting of 2 Gy of TBI with or
ithout ﬂudarabine [17,18]. Most conventional trans-
lant recipients received methotrexate and cyclospor-
ne (CSP) for graft-versus-host disease (GVHD) pro-
hylaxis [19], and all nonmyeloablative transplant
ecipients received mycophenolate mofetil and CSP
or that purpose [17,18]. Granulocyte colony-stimu-
ating factor (G-CSF) was not given routinely after
ransplantation. Diagnosis and clinical grading of
cute and chronic GVHD were performed according
o established criteria [20,21]. GVHD was treated
ith 1 to 2 mg/kg/d of prednisolone equivalents, re-
umption of full-dose CSP administration (if applica-
le), or both. Initial doses of corticosteroids and ta-
ering schedules of immunosuppressive medications
ere modiﬁed at the discretion of the attending phy-
icians according to the presence or absence of malig-
ant cells and the severity of GVHD. r
B&MTInpatients were housed in rooms equipped with
igh-efﬁciency particulate air ﬁltration, but laminar
irﬂow was used only in the early years of the study
before 1995). Fluconazole (400 mg/d) was given to
ost patients without histories of IA from the start of
onditioning to day 75 after transplantation [22,23] or
onger for some patients who received corticosteroids
or treatment of GVHD. As part of a randomized
rotocol, a subset of patients without prior IA received
traconazole (200 mg/d intravenously or 2.5 mg/kg 3
imes daily by mouth) for antifungal prophylaxis [24].
retransplantation and posttransplantation antifungal
herapies of patients with histories of IA were admin-
stered at the discretion of the attending transplanta-
ion and Infectious Diseases physicians. In general,
ntifungal therapy was administered with the goal of
tabilizing radiographic abnormalities so that trans-
lantation could proceed. Amphotericin-based (n 
0) or azole-based (n  5) regimens were adminis-
ered after transplantation to prevent recurrent
nfection. Seven patients also received prophylactic
ranulocyte transfusions before engraftment. All other
nti-infective prophylactic and therapeutic drugs were
rovided according to standard protocols [25]. Pulmo-
ary toxicities, deﬁned as signs and symptoms of pul-
onary disease with no infectious etiology identiﬁed,
ere identiﬁed by chart review.
efinition of Invasive Fungal Infections
Invasive fungal infections were deﬁned as proven,
robable, or possible, according to the European Or-
anization for Research and Treatment of Cancer/
ycoses Study Group guidelines [26]. Brieﬂy, proven
isease required histopathologic or microbiologic
ocumentation of a fungus from biopsied tissues, and
nfection was considered probable if the fungus was
dentiﬁed from culture of bronchoalveolar lavage or
putum when consistent signs and symptoms were
resent. The day of diagnosis of the fungal infection
as the day on which the ﬁrst positive diagnostic test
as performed. For patients whose diagnosis was es-
ablished after death, the date of death was considered
o be the day of diagnosis. Lesions that recurred in the
riginal anatomic location within the ﬁrst 100 days
fter HCT were considered to be recurrent; all others
ere considered to be newly acquired cases of IA.
tatistical Analyses
The probabilities of posttransplantation IA and
RM were estimated by cumulative incidences, where
eath and relapse of underlying malignancies were
egarded as competing risks. Overall survival after
ransplantation was estimated by using Kaplan-Meier
urves. Characteristics of groups categorized by a his-
ory of IA were compared with t tests or Wilcoxon
2ank sum tests for continuous variables and  tests for
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4ategorical factors. Log-rank tests were used to com-
are the hazards of IA and TRM after transplantation
ver time across patient subgroups. The Fisher exact
est was used to compare the incidence of pulmonary
oxicities by receipt of TBI-containing conditioning.
For analysis of IA and TRM in patients with prior
A, host factors of interest included patient age, un-
erlying disease risk, and pretransplantation cytomeg-
lovirus (CMV) serostatus. Transplantation character-
stics included conditioning regimen (TBI-based
onventional versus non–TBI-based conventional or
onmyeloablative), hematopoietic stem cell source
bone marrow versus peripheral blood versus cord
lood), donor type (related versus unrelated), HLA
ismatch between donor and recipient, and donor
MV serostatus. Factors related to prior IA and its
herapy included the certainty of the prior IA diagno-
is (proven or probable versus possible), anatomic site
f infection, pretransplantation chest x-ray (abnormal
ersus normal), lung surgery, extent of prior lung IA
focal versus multifocal or bilateral inﬁltrates), type of
rior lung IA (nodular and/or cavity versus inﬁltra-
ive), and duration of pretransplantation antifungal
herapy (30 versus 30 days; 60 versus 60 days).
cute GVHD and engraftment (absolute neutrophil
ount 500/mm3) were treated as time-dependent
ovariates in Cox regression models for recurrent IA.
iven the low numbers of patients and events, only 2
ovariates were assessed at a time in multiple Cox
egression models. Factors with univariate P values of
.2 were considered for inclusion in the multiple
egression models.
Two-sided P values from ﬁtted regression models
ere derived from the Wald test. No adjustments
ere made for multiple comparisons; P values .05
ere considered to be statistically signiﬁcant.
ESULTS
A before Allogeneic HCT
Forty-ﬁve patients with histories of IA were iden-
iﬁed among 2319 patients before ﬁrst allogeneic
CT; this represented 1.9% of the total allogeneic
CT recipients. Thirty-two cases were classiﬁed as
roven IA, 5 as probable IA, and 8 as possible IA.
natomic sites of infection included lungs (n  34),
inus (n  12), spleen (n  1), and external ear canal
nd mastoid bone (n  1). Three patients had both
roven sinus IA and probable lung IA. Among the 34
atients with pulmonary IA, 13 showed focal lung
esions and 21 showed nonfocal lesions; 22 had nod-
lar lesions with or without a cavity, and 12 had more
iffuse inﬁltrative lung lesions.
The median duration of antifungal treatment be-
ore HCT was 100 days (range, 7-2422 days). All 45
atients received amphotericin-based regimens for w
96reatment of pretransplantation IA; 5 also received
oriconazole, and 2 received caspofungin in combina-
ion with amphotericin-based regimens. Thirteen pa-
ients underwent surgery, which included lobectomy
r wedge resection of the lung. Among the 34 patients
ith prior lung IA, pretransplantation chest x-rays at
he time of HCT were abnormal in 19 and were either
ormal or showed scars after antifungal therapy
nd/or lung surgery in 15.
atient and Transplantation Characteristics
Patient and transplantation characteristics of the
319 ﬁrst allogeneic HCT recipients stratiﬁed by his-
ory of IA are summarized in Table 1. The median
ollow-up time was 507 days (range, 1-3573 days) after
CT; more than 75% of patients were followed up
or at least 100 days after transplantation. Median ages
ere 34 years (range, 2-70 years) and 39 years (range,
-73 years) for patients with or without histories of IA,
espectively (P  .020). Aspergillosis before HCT
ccurred more frequently among patients with acute
eukemia (73% versus 36%). The distributions of do-
or type, cell source, and conditioning regimen also
iffered signiﬁcantly between groups: more patients
ith prior IA received grafts from unrelated donors
60% versus 43%), received G-CSF–mobilized pe-
ipheral blood stem cells (PBSC) rather than bone
arrow (33% versus 20%), and received nonmyelo-
blative conditioning (17% versus 4%). All of these
herapeutic factors were associated with transplanta-
ion during more recent years.
ncidence of Posttransplantation IA and Survival
utcomes
The incidence of proven or probable IA diagnosed
fter transplantation was signiﬁcantly higher among
atients with histories of IA compared with those
ithout prior IA (22% versus 7% at day 100; 29%
ersus 10% at 1 year; P  .001; Figure 1A). Thirteen
atients with histories of IA developed posttransplan-
ation IA between day 1 and day 242 after HCT.
osttransplantation IA was found in the original ana-
omic location in all but 2 cases. Ten patients devel-
ped IA within the ﬁrst 100 days, and 3 developed IA
t days 122, 190, and 242 after HCT. The median
imes to posttransplantation IA within 100 days after
CT were 26 and 54 days among patients with or
ithout prior IA, respectively (P  .030). Seven of the
atients with prior IA developed posttransplantation
A before neutrophil engraftment, 6 of whom died
efore engraftment.
All 13 patients with IA before HCT who subse-
uently developed posttransplantation IA died despite
ntifungal therapy. The overall survival of patients
ith histories of IA was signiﬁcantly worse compared
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Invasive Aspergillosis before Allogeneic HSCT
Bith those without prior IA (56% versus 77% at day
00; 37% versus 58% at 1 year; P  .001; Figure 1B).
he probability of TRM among patients with histo-
ies of IA was signiﬁcantly higher than in those with-
ut prior IA (38% versus 21% at day 100; 54% versus
2% at 1 year; P  .001; Figure 1C). Although most
f the difference in TRM was associated with recur-
ent IA, there was a trend toward an increased risk for
RM that was independent of recurrent infection
18% versus 16% at day 100; 27% versus 24% at 1
ear; P  .055).
Among 45 patients with histories of IA, 18 patients
ied of transplant-related causes within the ﬁrst 100
ays, and an additional 7 patients within 1 year after
ransplantation. A large number of deaths were due to
ulmonary complications among patients with prior
A. These included posttransplantation IA (n  13),
diopathic pneumonia syndrome/diffuse alveolar hem-
rrhage (n  5), and non-IA infectious pneumonias
n  5; Klebsiella species, CMV, respiratory syncytial
irus, Zygomycetes, and Acremonium species).
isk Factors for Posttransplantation IA and TRM
mong Patients with Prior IA
Six patients received antifungal therapy for 30
able 1. Patient and Transplantation Characteristics of Allogeneic HCT
Factor Y
atient age, y, median (range)
onditioning, No. patients (% total)
TBI-based conventional
Non–TBI-based conventional
Nonmyeloablative
onor, No. patients (% total)
Related
Unrelated
tem cell source, No. patients (% total)*
PBSC
Bone marrow
Cord blood
nderlying diagnosis, No. patients (% total)†
Acute leukemia
Other malignancy
Nonmalignant disease
isease risk, No. patients (% total)‡
Low
High
Peripheral blood stem cell (PBSC) group included 15 patients wh
Acute leukemia indicates acute myeloid leukemia (AML) and acute
syndrome (MDS), chronic myeloid leukemia (CML), chronic lym
tumors; nonmalignant disease indicates aplastic anemia, immun
binuria.
Patients were stratiﬁed on the basis of underlying disease, as descr
AML, MDS (refractory anemia with excess of blasts or excess bla
MM regardless of status, accelerated phase or blastic crisis of C
as nonmalignant diseases, any of the above diseases with unknow
MDS (refractory anemia with or without ringed sideroblasts).ays before proceeding to HCT because of severe r
B&MTplastic anemia (n 3) or refractory leukemia (n 3).
f these 6 patients, 4 developed IA within 100 days
fter HCT. In univariate analysis (Table 2), a shorter
uration of pretransplantation antifungal therapy
30 versus 30 days) was associated with increased
isks for posttransplantation IA (4/6 versus 6/39; P 
001; Figure 2A) and TRM (4/6 versus 14/39; P 
033, Figure 3A). Patients who received antifungal
herapy for 60 days had a trend toward a decreased
isk of posttransplantation IA compared with those
ho received antifungal therapy for 60 days (16%
ersus 36%; P  .14).
Additional risk factors for posttransplantation IA
ithin the ﬁrst 100 days after HCT included hema-
opoietic stem cell source (cord blood versus bone
arrow versus PBSC; 2/2 versus 6/28 versus 2/15;
 .001) and proven or probable diagnosis of prior IA
versus possible IA; 10/37 versus 0/8; P  .086). Fail-
re to engraft after HCT was also associated with an
ncreased risk of posttransplantation IA in a Cox re-
ression model. Probabilities of posttransplantation
A at day 100 were not signiﬁcantly different by con-
itioning regimens (TBI-based conventional, 26%;
on–TBI-based conventional or nonmyeloablative,
4%; P  .30). Among patients with a history of IA,
ents with or without Histories of Invasive Aspergillosis (IA)
History of IA
P Value45) No (n  2274)
0) 39 (1-73) .020
%) 1443 (63%)
%) 739 (32%)
%) 92 (4%) .001
%) 1285 (57%)
%) 989 (43%) .027
%) 451 (20%)
%) 1800 (79%)
) 23 (1%) .005
%) 822 (36%)
%) 1345 (59%)
%) 107 (5%) .001
%) 1345 (59%)
%) 929 (41%) .092
ved both PBSC and bone marrow.
ocytic leukemia (ALL); other malignancy indicates myelodysplastic
tic leukemia (CLL), lymphoma, multiple myeloma (MM), and other
encies, and other diseases such as paroxysmal nocturnal hemoglo-
eviously [32]: high risk was deﬁned as active, de novo, or relapsed
ansformation), myeloproliferative disorder, ALL, CLL, lymphoma,
r other tumors such as renal cell carcinoma. Low risk was deﬁned
se status or in remission except for MM, CML chronic phase, andRecipi
es (n 
34 (2-7
31 (69
6 (13
8 (18
18 (40
27 (60
15 (33
28 (62
2 (4%
33 (73
6 (13
6 (13
21 (47
24 (53
o recei
lymph
phocy
odeﬁci
ibed pr
sts in tr
ML, o
n diseaeceipt of TBI-based conventional conditioning was
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4ssociated with an increased risk of day 100 TRM
ompared with nonmyeloablative or non–TBI-based
onventional conditioning (TBI-based conventional,
igure 1. Cumulative incidence of invasive aspergillosis (IA), over-
ll survival (OS), and transplant-related mortality (TRM) among
llogeneic HCT recipients with or without histories of IA. A, The
umulative incidence of proven or probable IA was signiﬁcantly
igher among patients with histories of IA (broken line; n  45) as
ompared with those without prior IA (solid line; n  2274; 22%
ersus 7% at day 100; 29% versus 10% at 1 year; P  .001). B, The
S of patients with histories of IA (broken line; n  45) was
igniﬁcantly worse as compared with those without prior IA (solid
ine; n  2274; 56% versus 77% at day 100; 37% versus 58% at 1
ear; P  .001). C, The probability of TRM among patients with
istories of IA (broken line; n  45) was signiﬁcantly higher as
ompared with those without prior IA (solid line; n  2274; 38%
ersus 21% at day 100; 54% versus 32% at 1 year; P  .001).2%; non–TBI-based conventional or nonmyeloabla- (
98ive, 14%; P .024; Figure 3B). Patients who received
BI-based conditioning regimens showed a trend
o more pulmonary toxicities after HCT compared
ith those who received other conditioning regimens
15/31 versus 3/14; P  .11).
After adjusting for duration of pretransplantation
ntifungal therapy (30 versus 30 days), no other
actor was signiﬁcantly associated with day 100 IA.
onditioning regimen (TBI-based conventional ver-
us non–TBI-based conventional or nonmyeloabla-
ive) and duration of pretransplantation antifungal
herapy (30 versus 30 days) seemed to confound
ne another in the model for TRM; ie, neither factor
as signiﬁcantly associated with the outcome in a
ultiple regression model. Cell source and certainty
f prior IA diagnosis were not included in multiple
egression models because of small numbers.
We also analyzed the risks for posttransplantation
A only among a subset of patients who had a prior
iagnosis of IA that involved the lungs (n  34). In
hese patients, as in the larger group of patients with
rior IA, a shorter duration of pretransplantation an-
ifungal therapy (30 versus 30 days; 2/4 versus
/30; P  .048) and hematopoietic stem cell source
cord blood versus bone marrow versus PBSC; 2/2
ersus 4/20 versus 1/12; P  .002) were associated
ith increased risks of posttransplantation IA. There
as a trend toward an increased risk of posttransplan-
ation IA in patients with abnormal pretransplantation
hest x-ray as compared with patients with normal
retransplantation chest x-ray (6/19 versus 1/15; P 
064; Figure 2B). Pretransplantation lung surgery and
he extent and type of lung lesions did not signiﬁcantly
nﬂuence the probability of developing posttransplan-
ation IA.
To elucidate the combined importance of the 2
dentiﬁed risk factors before transplantation, we de-
ermined the probabilities of IA and overall survival
ithin patient subsets according to pretransplantation
ntifungal therapy and chest x-ray (Figure 4). For this
nalysis, high-risk patients were considered to be
hose who received 30 days of pretransplantation
ntifungal therapy or had pretransplantation abnor-
alities on chest x-ray, and low-risk patients were
onsidered to be those who received more than 30
ays of pretransplantation antifungal therapy and had
ormal chest x-rays before transplantation. High-risk
atients with prior IA (n  22) had a signiﬁcantly
igher incidence of posttransplantation IA and lower
urvival at 1 year after HCT as compared with those
ithout prior IA (45% versus 10%, P .001; and 23%
ersus 58%, P  .001, respectively). However, the
umulative incidence of posttransplantation IA and
verall survival among low-risk patients with prior IA
n  23) were not statistically different from those
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Invasive Aspergillosis before Allogeneic HSCT
Bmong patients without prior IA (13% versus 10%,
 .65; and 52% versus 58%, P  .47, respectively).
utcomes and Risks among Patients with Proven
nd Probable prior IA
Outcomes were also analyzed after the 8 patients
ith “possible IA” diagnoses were eliminated from the
able 2. Risk Factor Analysis for Posttransplantation Invasive Aspergil
llogeneic HCT among 45 Patients with Histories of IA
Factor
Total
No. No
uration of pretransplantation antifungal Rx (d)
<30 6
>30 39
<60 14
>60 31
onor
Related 18
Unrelated 27
onditioning regimen
TBI-based conventional 31
Non–TBI or nonmyeloablative 14
MV serostatus
D/R 11
D/R 6
Any D/R 28
atient age at transplantation (y)
<19 16
19-40 13
>40 16
isease risk*
Low 21
High 24
LA mismatch
No 26
Yes 19
tem cell source†
PBSC 15
Bone marrow 28
Cord blood 2
rior IA diagnosis
Proven/probable 37
Possible 8
rior IA lung involvement
No 11
Yes 34
cute GVHD grade‡
0 or I 13
II–IV 32
ngraftment‡
No 12
Yes 33
indicates donor; R, recipient.
Patients were stratiﬁed on the basis of underlying disease, as descr
acute myeloid leukemia, myelodysplastic syndrome (refractory a
liferative disorder, acute lymphocytic leukemia, chronic lym
accelerated phase or blastic crisis of chronic myeloid leukemia
nonmalignant diseases, any of the above diseases with unknown d
leukemia chronic phase, and myelodysplastic syndrome (refract
Peripheral blood stem cell (PBSC) group included 1 patient who
P values were determined by Cox regression models, with acute Gohort, leaving 37 patients with proven or probable IA I
B&MTefore HCT. Results were similar to those in the
verall analysis. Receipt of antifungal therapy for less
han 30 days before HCT, receipt of cord blood as
ompared with bone marrow or PBSC, presence of an
bnormal chest x-ray at the time of HCT, and delayed
eutrophil engraftment were associated with higher
isks of recurrent IA (data not shown). Probability of
) and Transplant-Related Mortality (TRM) within 100 Days after
100 IA,
nts (% Total) P Value
Day 100 TRM,
No. Patients (% Total) P Value
(67%) 4 (67%)
(15%) .001 14 (36%) .033
(36%) 7 (50%)
(16%) .14 11 (35%) .350
(11%) 5 (28%)
(30%) .21 13 (48%) .300
(26%) 16 (52%)
(14%) .30 2 (14%) .024
(9%) 3 (27%)
(50%) 3 (50%)
(21%) .24 12 (43%) .640
(25%) 6 (38%)
(31%) 4 (31%)
(13%) .70 8 (50%) .530
(14%) 6 (29%)
(29%) .21 12 (50%) .130
(27%) 11 (42%)
(16%) .47 7 (37%) .840
(13%) 4 (27%)
(21%) 12 (43%)
(100%) .001 2 (100%) .008
(27%) 18 (49%)
(0%) .086 0 (0%) .020
(27%) 4 (36%)
(21%) .75 14 (41%) .710
(38%)
(16%) .87
(58%)
(9%) .029
eviously [32]: high risk was deﬁned as active, de novo, or relapsed
with excess of blasts or excess blasts in transformation), myelopro-
c leukemia, lymphoma, multiple myeloma regardless of status,
her tumors such as renal cell carcinoma; low risk was deﬁned as
tatus or in remission except for multiple myeloma, chronic myeloid
mia with or without ringed sideroblasts).
d both PBSC and bone marrow.
and engraftment treated as treated as time-dependent covariates.losis (IA
Day
. Patie
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5fter the 8 patients with possible IA were eliminated
rom the analyses (data not shown).
ISCUSSION
Invasive infections with Aspergillus species are
ommon in patients who receive cytotoxic therapies
or hematologic malignancies, both before and after
CT [1,27-29], and clinicians are often faced with the
ilemma of balancing necessary cytotoxic therapies
ith the risk of infection-related death. With this
tudy, we sought to determine the answer to 2 primary
uestions: (1) are recurrent IA and TRM rates so high
n patients with histories of IA so as to make the HCT
nwise? and (2) are there pretransplantation variables
hat may affect overall outcomes? Our review sug-
ested that although the risk of TRM was still high in
igure 2. Invasive aspergillosis (IA) after allogeneic HCT among
atients with histories of IA. A, The cumulative incidence of proven
r probable IA was signiﬁcantly higher among patients with histo-
ies of IA who received pretransplantation antifungal therapy (Rx)
or 30 days (broken line; n  6) as compared with 30 days (solid
ine; n  39; 67% versus 15% at day 100; P  .001). B, Among
atients with histories of IA that involved the lungs, the cumulative
ncidence of proven or probable IA was somewhat higher in patients
hose pretransplantation chest x-ray (CXR) was abnormal (broken
ine; n 19) as compared to those with normal CXR (solid line; n
6; 32% versus 7% at day 100; P  .064).uch patients, patients with IA who had resolution of (
00adiographic abnormalities after receipt of more than
month of antifungal therapy had similar risks for
nfection and death to patients with no prior IA. The
onditioning regimen and stem cell source may affect
he risks for recurrent IA and TRM.
The probability of posttransplantation IA among
atients with histories of infection in this study (29%
t 1 year) was similar to that of the previous European
rganization for Research and Treatment of Cancer
tudy (33%; 16/48 patients) [3]. The absence of sen-
itive diagnostic tests and microbiology limit conclu-
ions with regard the to timing of acquisition; how-
ver, when considering the early onset of symptoms
nd anatomic site of involvement, it seemed that a
ubstantial number of patients developed recurrent
ather than newly acquired infection. Analysis of pre-
ransplantation variables revealed that a shorter dura-
ion of pretransplantation antifungal therapy and per-
igure 3. Transplant-related mortality (TRM) after allogeneic
CT among patients with histories of IA. A, The probability of
RM was signiﬁcantly higher among patients with histories of IA
ho received pretransplantation antifungal therapy (Rx) for 30
ays (broken line; n  6) compared with 30 days (solid line; n 
9; 67% versus 36% at day 100; P  .033). B, The probability of
RM was signiﬁcantly higher among patients with histories of IA
ho received high-dose (HD) TBI-based conventional condition-
ng (solid line; n  31) as compared with those who received
on–TBI-based conventional or nonmyeloablative conditioning
broken line; n  14; 52% versus 14% at day 100; P  .024).
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Invasive Aspergillosis before Allogeneic HSCT
Bistent radiographic abnormalities were associated
ith increased risks of posttransplantation IA. It was
ot possible to determine the optimal duration of
ntifungal therapy with these data, because the pa-
ients who underwent HCT with evidence of active
ulmonary infection were more likely to have a con-
ition warranting expedited conditioning therapy,
uch as relapsed malignancy. Our data also suggest
hat there may be a subset of patients with prior IA
ho essentially have “normal” risks for aspergillosis
fter transplantation; speciﬁcally, patients who re-
igure 4. Cumulative incidence of invasive aspergillosis (IA) and
verall survival (OS) after allogeneic HCT. Patients with prior IA
ho were at high risk (deﬁned by pretransplantation antifungal
herapy for 30 days or abnormal chest x-ray; broken line; n  22)
ad a signiﬁcantly higher incidence of posttransplantation IA (A)
nd lower survival (B) at 1 year after HCT as compared with those
ithout prior IA (solid line; n  2274; 45% versus 10%, P  .001;
nd 23% versus 58%, P  .001, respectively). However, the cumu-
ative incidence of posttransplantation IA (A) and survival (B)
mong patients with prior IA who were at low risk (deﬁned by
retransplantation antifungal therapy for 30 days and normal
hest x-ray; dotted line; n  23) were not statistically different from
hose among patients without prior IA (solid line; n  2274; 13%
ersus 10%, P  .65; and 52% versus 58%, P  .47, respectively).eived more than 1 month of antifungal therapy and s
B&MTad resolution of radiographic abnormalities before
onditioning had equivalent risks for infection and
eath compared with patients who had no IA history.
Prior case reports suggested successful control of
ecurrent invasive fungal infections by prophylactic
ranulocyte transfusion and G-CSF administration to
horten the duration of neutropenia after HCT [5,7-
]. Our study did demonstrate that failure to engraft
fter HCT was associated with an increased risk of
ecurrent IA. However, in our study, 7 patients re-
eived prophylactic granulocyte transfusions without
pparent beneﬁt. This lack of effect is consistent with
ecent data on granulocyte transfusion for the treat-
ent of infections [30,31], but the small numbers of
atients evaluated and the inherent selection bias as-
ociated with elected granulocyte therapy limit our
bilities to draw conclusions relating to utility. Stem
ell sources may affect the risk for recurrent infection.
n our study, 2 of 2 cord blood recipients with prior IA
eveloped post-HCT infection; it may be that de-
ayed engraftment in this setting may encourage
eactivation of pulmonary IA [30]. Finally, several
eports previously indicated that surgical resection
f lung lesions might reduce the risk of recurrent IA
fter HCT [10-16]. Our data failed to conﬁrm this
uggestion; however, this could be a function of
mall number of cases and variability in surgical ap-
roaches.
Several prior reports have described small series of
atients with histories of IA who underwent successful
llogeneic HCT with nonmyeloablative (2 Gy of TBI
lone) or reduced-intensity (ﬂudarabine, busulfan, and
ntithymocyte globulin; melphalan) conditioning reg-
mens [4-6]. Our data suggested that high-dose TBI-
ased conditioning was associated with an increased
isk for TRM, primarily because of pulmonary toxic-
ty, compared with the other regimens. Patients with
istories of IA may be more vulnerable to lung dam-
ge by high-dose TBI, other organisms, or local acti-
ation of inﬂammatory cytokines [32]. This observa-
ion, which should be conﬁrmed by more detailed
rospective studies, might have important implica-
ions for the selection of conditioning regimens for
atients with histories of IA.
This study has several strengths and weaknesses.
he most important limitation is that this retrospec-
ive study compared outcomes in groups of patients
ho differed with regard to underlying diseases and
ther transplant variables. Also, we did not routinely
erform sensitive screening tests to identify occult IA
n asymptomatic patients before transplantation. Fi-
ally, the low number of cases of recurrent IA limited
ur ability to perform multiple Cox regression models
o analyze the relative importance of multiple vari-
bles. However, prospective identiﬁcation of patients
ith histories of IA, use of conservative and consen-
us-derived deﬁnitions for IA, and evaluation of out-
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5omes among a very large cohort of allogeneic HCT
ecipients (n  2319) allowed us to make a number of
otentially therapeutically relevant observations.
In summary, our data indicate that a history of IA
s not an absolute contraindication for allogeneic
CT, especially if adequate therapy is administered
efore transplantation. These data suggest that pre-
ransplantation antifungal therapy should be given for
t least 30 days or longer until radiographic abnor-
alities become signiﬁcantly reduced or normalize.
onmyeloablative or non–TBI-based myeloablative
egimens might be preferable for the conditioning of
llogeneic HCT if underlying disease can be con-
rolled and the risk of graft rejection can be overcome.
ecause of delayed engraftment, cord blood trans-
lantation may be associated with increased risks for
eactivated disease. Additional methods to measure
isease activity and response to antifungal therapy (eg,
alactomannan antigenemia or polymerase chain re-
ction) may be useful in future strategies to stage IA
efore myeloablative HCT or subsequent immuno-
uppressive therapies.
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